There are some students in the department I work in who made a music video because they don't have enough funding to do experiments.

As another parody, I am bringing up the recent biosketch controversy. Basically, Republicans are absolutely convinced that scientists just waste taxpayer money all day, even though they need us to prove their points as long as we agree with them. Democrats also are involved with the latter part of that, but they don't complain as much. You can read about the biosketch change here.
by Ian Musgrave, Senior lecturer in Pharmacology at University of Adelaide

I was going to avoid blogging on this topic, but seeing as the story made the Australian with the headline “Chemicals in lipstick and cleaning products linked to early menopause”, I feel I have to weigh in a bit to avoid undue panic and the inevitable dangers of people hurling their lipsticks out the window at great speed. Also, there are issues of science communication and “the dose makes the poison”

New studies have found that a supplement of ghrelin - the "appetite hormone" - increased the sexual activity of mice.

Ghrelin is a gastrointestinal hormone that is released from the stomach, and is involved in the stimulation of our appetite by activating the brain's reward system. Since the brain's reward system also motivates us to seek a partner and to have sex, a group of researchers at the Sahlgrenska Academy decided to investigate whether ghrelin may also affect sexual behaviors. 

The answer is: yes, at least in mice.
In the largest study of opioids users done to-date, scholars analyzed records of 198,247 people in England who had been involved in drug treatment or the criminal justice system between 2005 and 2009. 

They found that opioid users were six times more likely to die prematurely than people in the general population. Almost one in ten of these deaths were due to suicide, more than four times the rate in the general population. The data recorded 3,974 deaths and their causes during this period. The study is the first to record age trends in opioid users' mortality and with age, the gap gets even wider. In the oldest 45-64 age-group, homicide was 27 times more common than in the general population. 
A team of scientists from Brazilian Agricultural Research Corporation Embrapa and the University of Brasilia have discovered tranquilizing properties in previously unknown protein fragments of coffee beans.

They did tests and found that these opioid peptides outperformed morphine in mice.

Human papillomavirus is a virus that is responsible for almost all cases of cervical cancer and the HPV vaccine can prevent 70 percent of those.

A new study by University of Texas Medical Branch at Galveston researchers indicates that only about half of the girls ages 11-12, the age recommended by the Centers for Disease Control, receive the vaccine.

Over 10 percent of patients using aspirin therapy for primary cardiovascular disease prevention shouldn't be doing so, according to a recent paper. 

They were likely either inappropriately prescribed it or do it over the counter, according to a new study that examined practice variations in aspirin therapy by accessing data from the National Cardiovascular Disease Registry Practice Innovation and Clinical Excellence (PINNACLE) Registry. The authors examined a nationwide sample of 68,808 patients receiving aspirin for primary cardiovascular disease prevention and evaluating aspirin guidelines by the American Heart Association, the U.S. Preventative Services Task Force, and other organizations.

Autism spectrum disorders affect 1 percent of children in the United States and hundreds of genetic and environmental factors have been implicated in increasing the risk. 

Scientists have previously reported that suramin, a drug used for almost a century to treat trypanosomiasis (sleeping sickness) reversed environmental autism-like symptoms in mice and now a new study in Molecular Autism suggests that a genetic form of autism-like symptoms in mice are also corrected with the drug, even when treatment was started in young adult mice. 
A new white paper finds little to no evidence for the effectiveness of opioid drugs in the treatment of long-term chronic pain, despite the explosive recent growth in the use of such drugs. 

The paper, which constitutes the final report of a seven-member panel convened by the National Institutes of Health  last September, finds that many of the studies used to justify the prescription of these drugs were either poorly conducted or of an insufficient duration. That makes prolific use of these drugs surprising, says Dr. David Steffens, chair of the psychiatry department at the University of Connecticut and one of the authors of the study. When it comes to long-term pain, he says, "there's no research-based evidence that these medicines are helpful."